REFERENCES
- Yusuf S, Pepine CJ, Garces C, et al. Effect of enalapril on myocardial infarction and angina pectoris in patients with low ejection fraction. Lancet. 1992; 340: 1173–1178
- Collaborative Group of Primary Prevention Project. Low dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Lancet. 2001; 357: 89–75
- Staedke SG, Kanga MR, Dorsey G, et al. Amiodaquine, sulfadioxone/pyrimethamine and combination therapy for treatment of falciparum malaria in Kampala, Uganda: a randomised trial. Lancet. 2001; 358: 368–374
- Shepherd J, Blauw GJ, Murphy MB, et al, on behalf of the PROSPER study group. Pravastatin in elderly individuals at risk of vascular disease: a randomised trial. Lancet 2002; 360: 1623–1630
- Wallenstein L, Wilcox RG, Weaver WD, et al, for the ESTEEM investigators. Oral ximelagatran for secondary prophylaxis after myocardial infarction. Lancet 2003; 362: 789–797
- Jochan D, Richter A, Hofmann L, et al. Adjuvant autologous renal tumour cell vaccine and risk of tumor progression in patients with renal cell carcinoma. Lancet. 2004; 362: 594–599
- Andrews DW, Scott CB, Speranto PW, et al. Whole brain irradiation therapy with or without stereotactic radiosurgery boost for patients with 1–3 brain metastases. Lancet 2004; 363: 1665–1672
- Ferreira-Gonzalea I, Busse JW, Heels-Ansdell D, et al. Problems with use of composite end points in cardiovascular trials: systematic review of randomised controlled trials. BMJ. 2007; 334: 786–788
- Horng S, Grudy C. Misunderstanding of clinical research. Ethics and Human Research. 2003; 25: 11–16
- Fetting JH, Siminoff CA, Piantadosi S, et al. Effects of patients’ expectations of benefit with standard breast cancer adjuvant therapy on participants in clinical trials. J Oncol. 1990; 8: 1476–1482
- Anonymous. Patients’ demands for prescriptions in primary care. Br Med J. 1995; 310: 1084–1085